Effect of Acanthopanax senticosus injection on the activities of human tumor necrosis factor and natural killer cell in blood in the patients with lung cancer.
- Author:
De-Bin HUANG
1
;
Rui-Zhi RAN
;
Zhao-Fen YU
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Aged; Eleutherococcus; chemistry; Female; Humans; Immunity, Cellular; drug effects; Immunoglobulin Isotypes; blood; Infusions, Intravenous; Killer Cells, Natural; drug effects; Lung Neoplasms; blood; immunology; pathology; Lymphotoxin-alpha; metabolism; Male; Middle Aged; Plants, Medicinal; chemistry; Polysaccharides; administration & dosage; isolation & purification; pharmacology; Tumor Necrosis Factor-alpha; metabolism
- From: China Journal of Chinese Materia Medica 2005;30(8):621-624
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo study the effect of Acanthopanax senticosus injection (ASI) on the activities of human tumor necrosis factor (TNF) and natural killer cell (NKC) in the patients with lung cancer and the underlying mechanism.
METHOD73 cases with lung cancer were randomly divided into two groups, namely, the treatment group (n = 39) and observation group (n = 34); 61 cases with or without other diseases were respectively divided into control A (n = 30) and B (n = 31) groups. The patients in treatment group were injected with ASI for 21 days. The activities of human TNF and NKC and the levels of IgG, IgA and IgM were detected respectively.
RESULTAfter injection with ASI the activity of TNF-alpha in treatment group was comparable with that in the two control groups and was significant lower that that in observation group. The activity of TNF-beta and the levels of IgA, IgG and IgM were significantly higher than those in observation group and two control groups (P < 0.01). The activity of NKC was also remarkably higher than observation and two control groups.
CONCLUSIONASI can regulate the cellular immunity and factor, indicating that ASI can be used as an assistant drug to regulate the function of cellular immunity in the patients with lung cancer.
